Pituitary and Growth Disorders: Pathology, Clinical Evaluation, Pharmacotherapy and Surgical Management

Connect pituitary regulation, hormone excess and deficiency, growth disorders, clinical investigation, pharmacotherapy and surgical management in one rapid-revision framework.

1. The Topic in One Connected Flow

Pituitary disorders become easier to understand when three ideas are connected: normal hypothalamic control, abnormal hormone secretion, and the anatomical effect of a sellar mass. These changes produce recognizable clinical syndromes, guide investigation, and determine whether treatment should replace a deficient hormone, suppress an excessive hormone, block its action, or remove the tumor.

NORMAL CONTROL

Hypothalamus
GHRH, somatostatin, dopamine, CRH, TRH and GnRH regulate anterior-pituitary secretion.

→

PITUITARY DISTURBANCE

Adenoma, compression or ischemic injury
Functioning tumors cause hormone excess; destructive or compressive disease causes deficiency.

→

FUNCTIONAL CHANGE

Abnormal endocrine signaling
GH excess raises IGF-1; prolactin excess suppresses GnRH; trophic-hormone loss reduces target-gland function.

→

CLINICAL EFFECT

Recognizable syndrome
Acromegaly, gigantism, hyperprolactinemia, hypopituitarism, growth failure or visual-field disturbance develops.

→

DIAGNOSTIC CLUE

Hormone testing + pituitary MRI
Biochemistry identifies the abnormal axis; MRI defines tumor size and relation to the optic chiasm.

→

INTERVENTION

Target the dominant abnormality
Replace deficient GH, suppress GH with octreotide, block GH action with pegvisomant, suppress prolactin with dopamine agonists, or resect an appropriate adenoma.

→

OUTCOME / COMPLICATION

Control disease and protect function
Reduce endocrine complications, preserve vision and monitor for hypopituitarism, CSF leak, diabetes insipidus or postoperative electrolyte disturbance.

2. Key Clinical Connections

GH Excess → Acromegaly or Gigantism

Somatotroph adenoma → GH excess → ↑ IGF-1 → skeletal and soft-tissue overgrowth.

Before epiphyseal closure → excessive linear growth → gigantism.
After closure → acral and facial enlargement → acromegaly.

Prolactin Excess → Reproductive Dysfunction

Prolactinoma or reduced dopamine inhibition → ↑ prolactin → suppression of GnRH → reduced FSH/LH.

Result → amenorrhea, infertility or hypogonadism → dopamine agonist therapy reduces prolactin and tumor activity.

Pituitary Mass → Visual and Hormonal Effects

Macroadenoma expansion → optic-chiasm compression → bitemporal visual-field loss.

Compression of normal gland → hypopituitarism → deficient target-gland hormones and need for appropriate replacement.

3. AIM High-Yield Integration Review

⭐ Pituitary anatomy → visual defect: the gland lies below the optic chiasm, so suprasellar tumor expansion can produce bitemporal hemianopia.

⭐ GH excess → IGF-1 elevation: somatotroph adenoma increases GH activity, producing soft-tissue and skeletal overgrowth plus metabolic complications.

Acromegaly investigation → interpretation: raised age-adjusted IGF-1 suggests GH excess; failure of GH suppression after oral glucose supports the diagnosis.

⭐ Dopamine → prolactin control: dopamine suppresses lactotroph secretion, so dopamine agonists such as bromocriptine reduce prolactin and prolactinoma activity.

Octreotide → GH suppression: somatostatin-receptor activation reduces GH and IGF-1; gastrointestinal effects, gallstones and altered glucose regulation are important cautions.

Sheehan syndrome → hormone deficiency: severe postpartum hypoperfusion damages the enlarged anterior pituitary, producing failure of lactation and other pituitary deficiencies.

⭐ Short stature → growth pattern: height velocity, target height and bone age help distinguish normal growth variants from GH deficiency or systemic disease.

Macroadenoma → surgical principle: transsphenoidal surgery aims to remove or debulk tumor and decompress critical structures while preserving normal pituitary function.

AIM Exam Trap: GH excess is treated through different targets: octreotide suppresses GH secretion, while pegvisomant blocks the GH receptor. These mechanisms should not be confused.